Fatos Dilan Koseoglu Atilla1, Basak Ozgen Saydam2, Nihat Ali Erarslan3, Ayse Gulden Diniz Unlu4, Hamiyet Yilmaz Yasar5, Muhammet Ozer6, Baris Akinci7. 1. Department of Internal Medicine, Tepecik Training and Research Hospital, 35180,, Izmir, Turkey. 2. Division of Endocrinology and Metabolism, Dokuz Eylul University Faculty of Medicine, 35340,, Izmir, Turkey. basakozgen@gmail.com. 3. Department of Radiology, Tepecik Training and Research Hospital, 35180,, Izmir, Turkey. 4. Department of Pathology, Tepecik Training and Research Hospital, 35180,, Izmir, Turkey. 5. Division of Endocrinology and Metabolism, Tepecik Training and Research Hospital, 35180,, Izmir, Turkey. 6. Department of Internal Medicine, Dokuz Eylul University Faculty of Medicine, 35340,, Izmir, Turkey. 7. Division of Endocrinology and Metabolism, Dokuz Eylul University Faculty of Medicine, 35340,, Izmir, Turkey.
Abstract
INTRODUCTION: The American College of Radiology (ACR) has recently proposed a guideline that recommends clinicians to perform thyroid fine-needle aspiration biopsy (FNAB) on the basis of ultrasound features. In this study, we focused on nodules for which no biopsy is recommended by the ACR Thyroid Imaging, Reporting and Data System (TI-RADS) guideline. SUBJECTS AND METHODS: Two-thousand eight-hundred and forty-seven consecutive patients with thyroid nodules who underwent FNAB according to the 2009 American Thyroid Association (ATA) guideline were included. The nodules were re-classified according to the ACR TI-RADS guideline as benign (TR1), not suspicious (TR2), mildly suspicious (TR3), moderately suspicious (TR4) and highly suspicious (TR5). The TR3 category was stratified into two subcategories as regard to the nodule size (TR3; <25 mm and TR3; ≥25 mm). RESULTS: Two-hundred and thirty-three (8.2%) patients with non-diagnostic FNABs were excluded. When the TR2 and TR3; <25 mm categories were merged, FNAB was suggestive of thyroid cancer in 17 of 1382 patients (1.2%). FNAB revealed Bethesda IV-VI in 5 of 273 patients with the TR3; ≥25 mm category (1.8%), in 61 of 896 patients with the TR4 category (6.8%), and in 18 of 63 of patients with the TR5 category (28.6%). The ACR TI-RADS scoring was 98.8% (95% CI: 98 to 99.3) specific for identification of a benign nodule. CONCLUSION: Our data suggest that ACR TI-RADS scoring is an applicable and potentially cost-effective approach to determine thyroid nodules to be biopsied, although a small proportion of thyroid cancers would be missed.
INTRODUCTION: The American College of Radiology (ACR) has recently proposed a guideline that recommends clinicians to perform thyroid fine-needle aspiration biopsy (FNAB) on the basis of ultrasound features. In this study, we focused on nodules for which no biopsy is recommended by the ACR Thyroid Imaging, Reporting and Data System (TI-RADS) guideline. SUBJECTS AND METHODS: Two-thousand eight-hundred and forty-seven consecutive patients with thyroid nodules who underwent FNAB according to the 2009 American Thyroid Association (ATA) guideline were included. The nodules were re-classified according to the ACR TI-RADS guideline as benign (TR1), not suspicious (TR2), mildly suspicious (TR3), moderately suspicious (TR4) and highly suspicious (TR5). The TR3 category was stratified into two subcategories as regard to the nodule size (TR3; <25 mm and TR3; ≥25 mm). RESULTS: Two-hundred and thirty-three (8.2%) patients with non-diagnostic FNABs were excluded. When the TR2 and TR3; <25 mm categories were merged, FNAB was suggestive of thyroid cancer in 17 of 1382 patients (1.2%). FNAB revealed Bethesda IV-VI in 5 of 273 patients with the TR3; ≥25 mm category (1.8%), in 61 of 896 patients with the TR4 category (6.8%), and in 18 of 63 of patients with the TR5 category (28.6%). The ACR TI-RADS scoring was 98.8% (95% CI: 98 to 99.3) specific for identification of a benign nodule. CONCLUSION: Our data suggest that ACR TI-RADS scoring is an applicable and potentially cost-effective approach to determine thyroid nodules to be biopsied, although a small proportion of thyroid cancers would be missed.
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: L Leenhardt; G Hejblum; B Franc; L D Fediaevsky; T Delbot; D Le Guillouzic; F Ménégaux; C Guillausseau; C Hoang; G Turpin; A Aurengo Journal: J Clin Endocrinol Metab Date: 1999-01 Impact factor: 5.958
Authors: Franklin N Tessler; William D Middleton; Edward G Grant; Jenny K Hoang; Lincoln L Berland; Sharlene A Teefey; John J Cronan; Michael D Beland; Terry S Desser; Mary C Frates; Lynwood W Hammers; Ulrike M Hamper; Jill E Langer; Carl C Reading; Leslie M Scoutt; A Thomas Stavros Journal: J Am Coll Radiol Date: 2017-04-02 Impact factor: 5.532
Authors: Sophia C Kamran; Ellen Marqusee; Mathew I Kim; Mary C Frates; Julie Ritner; Hope Peters; Carol B Benson; Peter M Doubilet; Edmund S Cibas; Justine Barletta; Nancy Cho; Atul Gawande; Daniel Ruan; Francis D Moore; Karla Pou; P Reed Larsen; Erik K Alexander Journal: J Clin Endocrinol Metab Date: 2012-12-28 Impact factor: 5.958
Authors: Asher A Mendelson; Michael Tamilia; Juan Rivera; Michael P Hier; Mark Sherman; Natasha Garfield; Martin J Black; Louise Rochon; Olguta Gologan; Richard J Payne Journal: J Otolaryngol Head Neck Surg Date: 2009-06
Authors: Dario Tumino; Giorgio Grani; Marta Di Stefano; Maria Di Mauro; Maria Scutari; Teresa Rago; Laura Fugazzola; Maria Grazia Castagna; Fabio Maino Journal: Front Endocrinol (Lausanne) Date: 2020-01-23 Impact factor: 5.555